Tibotec Presents Interim Findings for TMC435, an Investigational Genotype 1 Hepatitis C Treatment, at the AASLD Liver ... (FinanzNachrichten)
Cork, Ireland, November 20 (ots/PRNewswire) - - Nearly 90 Percent of Patients Achieve Undetectable Viral Load in Phase IIa Trial Within 28 Days of Combined ...
Tibotec Presents Interim Findings for TMC435, an Investigational Genotype 1 Hepatitis C Treatment, at the AASLD Liver ... (Presseportal)
Cork, Ireland, November 20 (ots/PRNewswire) - - Nearly 90 Percent of Patients Achieve Undetectable Viral Load in Phase IIa Trial Within 28 Days of Combined Treatment With Standard of Care New clinical data demonstrate the safety and antiviral activity of TMC435, an investigational protease inhibitor (PI) being developed by Tibotec BVBA for the treatment of chronic hepatitis C virus (HCV) ...
Tibotec Presents Interim Findings for TMC435, an Investigational Genotype 1 Hepatitis C Treatment, at the AASLD Liver ... (PR Newswire via Yahoo! Finance)
New clinical data demonstrate the safety and antiviral activity of TMC435, an investigational protease inhibitor being developed by Tibotec BVBA for the treatment of chronic hepatitis C virus infection.
Top Scoops (Scoop.co.nz)
To gain approval for treating children, all a drug company has to do is submit two positive studies to the FDA to prove a medication is safe and effective for kids.
Medivation Announces Upcoming Data Presentations on Dimebon's Mechanism of Action (PR Newswire via Yahoo! Finance)
Medivation, Inc. today announced that new data about the mechanism of action of Dimebon, its lead product candidate in development to treat Alzheimer's and Huntington's diseases, will be presented at upcoming scientific conferences:
